Trip.com Group Limited [TCOM] Securities Class Action Lawsuit Update

• Case Name: De Wilde v. Trip.com Group Limited et al.
• Case No.: 1:26-cv-01420
• Jurisdiction: U.S. District Court, Eastern District of New York
• Filed on: March 11, 2026
• Class Period: April 30, 2024 - January 13, 2026

Introduction

Trip.com Group Limited now faces a securities class action in the Eastern District of New York after investors alleged the company materially understated the regulatory danger posed by its dominant position in China’s online travel market. The complaint defines a class period from April 30, 2024 through January 13, 2026 and names CEO Jane Jie Sun and CFO Cindy Xiaofan Wang as defendants alongside the company.

At the center of the case is a familiar securities fraud theory with unusually sharp edges: investors allege Trip.com repeatedly framed antitrust enforcement as a hypothetical risk even as Chinese regulators were already intensifying scrutiny of platform businesses and the company’s market conduct. The alleged truth emerged when Bloomberg reported that China had opened an antitrust probe into Trip.com, triggering a steep one-day selloff in the ADSs.

For investors, the case centers on whether Trip.com’s risk disclosures presented an active regulatory threat as merely hypothetical, and whether the January 14, 2026 disclosure revealed information the market had not previously absorbed.

“Most TCOM shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.

Backdrop and Business Context

Trip.com describes itself as a leading global one-stop travel services platform, serving travelers across Asia and increasingly worldwide through booking, content, customer support, and technology infrastructure. Its ADSs trade on the NASDAQ under ticker symbol TCOM.

That business model matters to the allegations. The complaint ties the company’s scale, strategic investments, and historical acquisitions to its dominant market position, particularly in China’s online travel ecosystem. The filing repeatedly references the company’s prior Qunar transaction and other strategic investments as areas exposed to Chinese anti-monopoly review.

The lawsuit’s narrative turns on the structural tension between market dominance and disclosure duties. A platform business can enjoy the economics of concentration right up until regulators decide those economics are exclusionary. According to the complaint, Trip.com’s disclosures acknowledged this possibility in form, but not in substance.

Promises Made vs. Reality

The complaint focuses on nearly identical risk disclosures in Trip.com’s 2023 and 2024 Form 20-F filings. In both years, the company warned that its investment and acquisition strategy “could” be adversely affected by anti-monopoly laws and that Chinese regulators might impose penalties or restrictive measures.

Investors allege those statements were misleading because they converted an allegedly mounting regulatory reality into a conditional future possibility. The complaint states that defendants “recklessly understated the regulatory risk facing Trip.com as a result of its monopolistic business activities.”

This is the hinge point of the case. The company did not omit antitrust risk entirely. Instead, plaintiffs argue it described the danger in the grammar of uncertainty while the enforcement climate in China had already become concrete, active, and directed toward dominant digital platforms.

The distinction is subtle. The market reaction suggests investors considered it material.

Timeline of Alleged Misconduct and Disclosures

The alleged misconduct begins on April 29, 2024, when Trip.com filed its 2023 Form 20-F with SEC certifications signed by Sun and Wang. That filing included detailed PRC Anti-Monopoly Law risk disclosures that plaintiffs now say materially understated the immediacy of enforcement risk. The same theory extends into the April 11, 2025 Form 20-F, where the company again warned that anti-monopoly laws in relevant jurisdictions “could” affect strategic investments and acquisitions.

The corrective disclosure arrived on January 14, 2026. Bloomberg reported that China had launched an antitrust probe into Trip.com, with the State Administration for Market Regulation accusing the company of abusing its market position and engaging in monopolistic practices. The article also noted that scrutiny of the sector had been building for months, including prior meetings with regulators in Guizhou and Zhengzhou.

That same day, TCOM ADSs fell $12.90, or 17.05%, closing at $62.78. The next day, they fell another $1.48, or 2.35%, to $61.30.

A disclosure timeline does not need drama when the price chart supplies it.

Investor Harm and Market Reaction

The complaint explicitly ties investor harm to the January 14, 2026 Bloomberg report and the resulting collapse in Trip.com’s ADS price. The two-day decline erased more than $14 per ADS in market value, which plaintiffs contend reflected the release of previously concealed regulatory risk into an efficient market.

The market’s reaction is central to plaintiffs’ loss causation allegations. Plaintiffs argue the revelation was not simply “bad news,” but the materialization of a risk long embedded in the company’s business model and allegedly softened in prior SEC filings.

From an investor perspective, the legal significance lies in the sequence: risk language, regulatory reveal, immediate repricing.

That causal chain is the architecture of many successful Section 10(b) cases.

Litigation and Procedural Posture

The complaint asserts claims under Section 10(b) and Rule 10b-5 against all defendants, plus Section 20(a) control-person claims against Sun and Wang.

Scienter allegations are built around executive access and control. Plaintiffs allege the individual defendants directly participated in management, reviewed and approved SEC filings, signed SOX certifications, and either knew or recklessly disregarded the falsity of the company’s risk disclosures.

Notably, the complaint does not rely on insider sales allegations or confidential witnesses. Instead, it leans on the theory that senior management necessarily understood the regulatory implications of the company’s dominant market conduct in China.

Shareholder Sentiment

Public retail investor commentary following the January 14, 2026 disclosure reflected a shift toward caution, with discussions on platforms such as Stocktwits and Reddit focusing on regulatory uncertainty and the potential financial impact of an antitrust investigation in China. In general, retail sentiment appeared to center on concerns about fines, operational restrictions, and the broader implications of increased scrutiny on dominant platform companies.

While some investors framed the selloff as a potential buying opportunity tied to long-term travel demand, others questioned management’s prior risk disclosures and whether the regulatory environment had been more advanced than previously understood. Overall, the tone of retail discussion reflected heightened uncertainty rather than a clear consensus direction, consistent with reactions typically observed following unexpected regulatory developments.

Analyst Commentary

Financial news coverage following the January 14, 2026 disclosure focused on the potential implications of China’s antitrust probe for Trip.com’s market position and future growth assumptions. Bloomberg reported that the State Administration for Market Regulation had opened an investigation into the company’s alleged monopolistic practices, highlighting broader regulatory scrutiny of dominant online platforms in China. Reuters similarly noted that the probe targeted Trip.com’s position as the country’s largest online travel agency, raising the prospect of penalties or operational constraints.

While specific analyst downgrades or price-target revisions were not widely reported in initial coverage, financial commentary generally emphasized that antitrust investigations into platform companies can introduce uncertainty around key drivers such as pricing power, merchant relationships, and expansion strategies. In that context, the reported probe was framed as a development that could affect how investors and analysts assess Trip.com’s risk profile going forward, particularly in light of China’s evolving regulatory environment for large technology-enabled platforms.

SEC Filings & Risk Factors

The complaint places substantial emphasis on the company’s risk disclosures.

Trip.com’s 2023 and 2024 Form 20-F filings expressly discussed PRC anti-monopoly law, SAMR review, acquisition scrutiny, potential penalties, fines up to 10% of prior-year revenue, and even the possibility that transactions could be unwound. Plaintiffs do not argue the company failed to mention the risk. They argue the filings mischaracterized the timing and immediacy of that risk.

According to the complaint, plaintiffs contend the company’s disclosures described antitrust danger as a future possibility even though Chinese regulatory scrutiny had already intensified. Here, the complaint alleges Chinese regulatory scrutiny had already been intensifying, making the company’s hypothetical framing materially misleading.

Conclusion: Implications for Investors

The complaint against Trip.com centers on whether the company’s risk-factor disclosures materially understated the immediacy of antitrust enforcement risk in China. Plaintiffs allege that when Bloomberg reported on January 14, 2026 that Chinese regulators had opened an antitrust probe into the company, the market reacted sharply, causing Trip.com’s ADSs to decline over two trading days. Whether those allegations ultimately survive motion practice will depend on the sufficiency of the pleaded facts and any later-developed evidence.

How to Join the Trip.com Group Limited (TCOM) Class Action

• Confirm you purchased TCOM shares during the April 30, 2024 through January 13, 2026 class period
• Review eligibility details in the filed complaint and class definition
• Click here to check eligibility

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.